Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

BACKGROUND: Pembrolizumab is FDA approved for tumors with tumor mutational burden (TMB) of ≥10 mutations/megabase (mut/Mb). However, the response to immune checkpoint inhibitors (ICI) varies significantly among cancer histologies. We describe the landscape of frameshift mutations (FSs) and evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Florou, Vaia, Floudas, Charalampos S, Maoz, Asaf, Naqash, Abdul Rafeh, Norton, Carter, Tan, Aik Choon, Sokol, Ethan S, Frampton, Garrett, Soares, Heloisa P, Puri, Sonam, Swami, Umang, Wilky, Breelyn, Hosein, Peter, Trent, Jonathan, Lopes, Gilberto de Lima, Park, Wungki, Garrido-Laguna, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432623/
https://www.ncbi.nlm.nih.gov/pubmed/37586768
http://dx.doi.org/10.1136/jitc-2023-007440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432623/
https://www.ncbi.nlm.nih.gov/pubmed/37586768
http://dx.doi.org/10.1136/jitc-2023-007440

Ejemplares similares